Evidence for positive selection in the C-terminal domain of the cholesterol metabolism gene PCSK9 based on phylogenetic analysis in 14 primate species

PLoS ONE

Volumn 2, Issue 10, 2007, Pages

  Ding, Keyue ^a   McDonough, Samantha J ^a   Kullo, Iftikhar J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PCSK9 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

AMINO ACID ANALYSIS; ARTICLE; CARBOXY TERMINAL SEQUENCE; CHOLESTEROL METABOLISM; CONTROLLED STUDY; EVOLUTIONARY HOMOLOGY; GENE FUNCTION; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; MONKEY; NONHUMAN; NUCLEOTIDE SEQUENCE; ORANG UTAN; PHYLOGENY; PRIMATE; PROTEIN DETERMINATION; SEQUENCE HOMOLOGY; AMINO ACID SEQUENCE; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; GENETICS; METABOLISM; MOLECULAR EVOLUTION; MOLECULAR GENETICS; MUTATION; PROTEIN TERTIARY STRUCTURE; SPECIES DIFFERENCE;

CERCOPITHECIDAE; HOMO; PLATYRRHINI; PONGO PYGMAEUS; PRIMATES;

AMINO ACID SEQUENCE; ANIMALS; CHOLESTEROL; CHOLESTEROL, LDL; EVOLUTION, MOLECULAR; HUMANS; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; MUTATION; PRIMATES; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, LDL; SEQUENCE HOMOLOGY, AMINO ACID; SERINE ENDOPEPTIDASES; SPECIES SPECIFICITY;

EID: 42549089208     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0001098     Document Type: Article

References (73)

1. Espenshade PJ, Cheng D, Goldstein JL, Brown MS (1999) Autocatalytic processing of site-1 protease removes propeptide and permits cleavage of sterol regulatory elcment-binding proteins. J Biol Chem 274: 22795-22804.
2. Brown MS, Goldstein JL (1999) A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc Natl Acad Sci U S A 96: 11041-11048.
3. Elagoz A, Benjannet S, Mammarbassi A, Wickham L, Seidah NG (2002) Biosynthesis and cellular trafficking of the convertase SKI-1/SIP: ectodomain shedding requires SKI-1 activity. J Biol Chem 277: 11265-11275.
4. Benjannet S, Rhainds D, Essalmani R, Mayne J, Wickham L, et al. (2004) NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem 279: 48865-48875.
5. Naureckicne S, Ma L, Sreekumar K, Purandare U, Lo CF, et al. (2003) Functional characterization of Narc 1, a novel proteinase related to proteinase K. Arch Biochem Biophys 420: 55-67.
6. Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, et al. (2003) The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A 100: 928-933.
7. Lalanne F, Lambert G, Amar MJ, Chetiveaux M, Zair Y, et al. (2005) Wild-type PCSK9 inhibits-LDL clearance but dbes not affect apoB-oontaining lipoprotein production in mouse and cultured cells. J Lipid Res 46: 1312-1319.
8. Maxwell KN, Breslow JL (2004) Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci U S A 101: 7100-7105.
9. Park SW, Moon YA, Horton JD (2004) Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J Biol Chem 279: 50630-50638.
10. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, et al. (2003) Mutations in PCSK9 cause autosomal dominant hypercholesttrolemia. Nat Genet 34: 154-156.
11. Leren TP (2004) Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia. Clin Genet 65: 419-422.
12. Timms KM, Wagner S, Samuels ME, Forbey K, Goldfine U, et al. (2004) A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum Genet 114: 349-353.
13. Sun XM, Eden ER, Tosi I, Neuwirth CK, Wile D, et al. (2005) Evidence for effect of mutant PCSK9 on apolipoproicin B secretion as the cause of unusually severe dominant hypercholesterolaemia. Hum Mol Genet 14: 1161-1169.
14. Naoumova RP, Tosi I, Patel D, Neuwirth C, Horswell SD, et al. (2005) Severe hypercholesterolemia in four British famlies with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response. Arterioscler Thromb Vasc Biol 25: 2654-2660.
15. Shioji K, Mannami T, Kokubo Y, Inamoto N, Takagi S, et al. (2004) Genetic variants in PCSK9 affect the cholesterol level in Japanese. J Hum Genet 49: 109-114.
16. Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, et al. (2005) Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 37: 161-165.
17. Kotowski IK, Pertsemlidis A, Luke A, Cooper RS, Vega CL, et al. (2006) A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet 78: 410-422.
18. Berge KE, Ose L, Leren TP (2006) Missense mutations in the PCSK9 gene are associated with hypocholcsterolemia and possibly increased response to statin therapy. Arterioscler Thromb Vasc Biol 26: 1094-1100.
19. Yue P, Averna M, Lin X, Schonfeld G (2006) The c.43_44insCTG variation in PCSK9 is associated with low plasma LDL-cholesterol in a Caucasian population. Hum Mutat 27: 460-466.
20. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH (2006) Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354: 1264-1272.
21. Fleagle JG, McGraw WS (1999) Skeletal and dental morphology supports diphyletic origin of baboons and mandrills. Proc Natl Acad Sci U S A 96: 1157-1161.
22. Crissey S, Barr J, Slifka K, Bowen P, Stacewicz-Sapuntzakis M, et al. (1999) Serum concentrations of lipids, vitamins A and E, vitamin D metabolites, and carotenoids in nine primate species at four zoos. Zoo biology 18: 551-564.
23. Caceres M, Lachucr J, Zapala MA, Redmond JC, Kudo I, et al. (2003) Elevated gene expression levels distinguish human from non-human primate brains. Proc Natl Acad Sci U S A 100: 13030-13035.
24. Horton JD, Goldstein JL, Brown MS (2002) SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109: 1123-1131.
25. Tall AR (2006) Protease variants LDL and coronary heart disease. N Engl J Med 354: 1310-1312.
26. Attie AD, Seidah NG (2005) Dual regulation of the LDL receptor-some clarity and new questions. Cell Metab 1: 290-292.
27. Seidah NG, Khatib AM, Prat A (2006) The proprotein convertases and their implication in sterol and/or lipid metabolism. Biol Chem 387: 871-877.
28. Yang Z, Nielsen R (2002) Codon-substitution models for detecting molecular adaptation at individual sites along specific lineages. Mol Biol Evol 19: 908-917.
29. Nei M, Kumar S (2000) Molecular evolution and phylogenctics. Oxford: Oxford University Press.
30. Messier W, Stewart CB (1997) Episodic adaptive evolution of primate lysozymes. Nature 385: 151-154.
31. Yang Z (1998) Likelihood ratio tests for detecting positive selection and application to primate lysozyme evolution. Mol Biol Evol 15: 568-573.
32. Huttley GA, Easteal S, Southey MC, Tesoriero A, Giles GG, et al. (2000) Adaptive evolution of the tumour suppressor BRCA1 in humans and chimpanzees. Australian Breast Cancer Family Study. Nat Genet 25: 410-413.
33. Sabeti PC, Schaffner SF, Fry B, Lohmueller J, Varilly P, et al. (2006) Positive natural selection in the human lineage. Science 312: 1614-1620.
34. Pond SL. Frost SD, Muse SV (2005) HvPhv: hypothesis testing using phylogenies. Bioinformatics 21: 676-679.
35. Lynn DJ, Freeman AR, Murray C, Bradley DG (2005) A genomics approach to the detection of positive selection in cattle: adaptive evolution of the T-cell and natural killer cell-surface protein CD2. Genetics 170: 1189-1196.
36. Hurst LD (2002) The Ka/Ks ratio: diagnosing the form of sequence evolution. Trends Genet 18: 486.
37. Goodman M, Porter CA, Czelusniak J, Page SI, Schneider H, et al. (1998) Toward a phylogenefic classification of Primates based on DNA evidence complemented by fossil evidence. Mol Phylogenet Evol 9: 585-598.
38. Nielsen R, Yang Z (1998) Likelihood models for detecting positively selected amino acid sites and applications to the HIV-1 envelope gene. Genetics 148: 929-936.
39. Yang, Z, Nielsen R, Goldman N, Pedersen AM (2000) Codon-substitution models for heterogeneous selection pressure at amino acid sites. Genetics 155: 431-449.
40. Yang Z, Wong WS, Nielsen R (2005) Bayes empirical bayes inference of amino acid sites under positive selection. Mol Biol Evol 22: 1107-1118.
41. Wong WS, Yang Z, Goldman N, Nielsen R (2004) Accuracy and power of statistical methods for detecting adaptive evolution in protein coding sequences and for identifying positively selected sites. Genetics 168: 1041-1051.
42. Self S, Liang K (1987) Asymptotic properties of maxinium likelihood estimators and likelihood ratio tests under non-standard conditions. J Am Stat Assoc 82: 605-610.
43. Horton JD, Cohen JC, Hobbs HH (2007) Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci 32: 71-77.
44. Mbikay M, Mayne J, Seidah NG, Chretien M (2007) Of PCSK9, cholesterol homeostasis and parasitic infections: Possible survival benefits of loss-of-function PCSK9 genetic polymorphisms. Med Hypotheses.
45. Olson MV (1999) When less is more: gene loss as an engine of evolutionary change. Am J Hum Genet 64: 18-23.
46. Perry GH, Tito RY, Verrelli BC (2007) The evolutionary history of human and chimpanzee Y-chromosome gene loss. Mol Biol Evol 24: 853-859.
47. Zhang J, Nielsen R, Yang Z (2005) Evaluation of an improved branch-site likelihood method for detecting positive selection at the molecular level. Mol Biol Evol 22: 2472-2479.
48. Anisimova M, Bielawski JP, Yang Z (2001) Accuracy so power of the likelihood ratio test in detecting adaptive molecular evolution. Mol Biol Evol 18: 1585-1592.
49. Purvis A (1995) A composite estimate of primate phylogeny. Philos Trans R Soc Lond B Biol Sci 348: 405-421.
50. McNutt MC, Lagace TA, Horton JD (2007) Catalytic activity is not required for secreted PCSK9 to reduce LDL receptors in HepC2 cells. J Biol Chem 282: 20799-20803.
51. Seidah NG, Prat A (2007) The proprotein convertases are potential targets in the treatment of dyslipidemia. J Mol Med 85: 685-696.
52. Nassoury N, Blasiole DA, Tebon Oler A, Benjannet S, Hamelin J, et al. (2007) The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR. Traffic 8: 718-732.
53. Enard W, Khaitovich P, Klose J, Zollner S, Heissig F, et al. (2002) Intra- and interspecific variation in primate gene expression patterns. Science 296: 340-343.
54. Poirier S, Prat A, Marcinkiewicz E, Paquin J, Chitramuthu BP, et al. (2006) Implication of the proprotein convertase NARC-1/PCSK9 in the development of the nervous system. J Neurochem 98: 838-850.
55. Rashid S, Curtis DE, Garuti R, Anderson NN, Bashmakov Y, et al. (2005) Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci U S A 102: 5374-5379.
56. Bingham B, Shen R, Kotnis S, Lo CF, Ozenberger BA, et al. (2006) Proapoptotic effects of NARC 1 (=PCSK9), the gene encoding a novel serine proteinase. Cytometry A 69: 1123-1131.
57. Hahn MW, Rockman MV, Soranzo N, Goldstein DB, Wray GA (2004) Population genetic and phylogenetic evidence for positive selection on regulatory mutations at the factor VII locus in humans. Genetics 167: 867-877.
58. Nakajima T, Wooding S, Sakagami T, Emi M, Tokunaga K, et al. (2004) Natural selection and population history in the human angiotensinogen gene (AGT): 736 complete ACT sequences in chromosomes from around the world. Am J Hum Genet 74: 898-916.
59. Thompson EE, Kuttab-Boulos H, Witonsky D, Yang L, Roe BA, et al. (2004) CYP3A variation and the evolution of salt-sensitivity variants. Am J Hum Genet 75: 1059-1069.
60. Rockman MV, Hahn MW, Soranzo N, Loisel DA, Goldstein DB, et al. (2004) Positive selection on MVP3 regulation has shaped heart disease risk. Curr Biol 14: 1531-1539.
61. Young JH, Chang YP, Kim JD, Chretien JP, Klag MJ, et al. (2005) Differential susceptibility to hypertension is due to selection during the out-of-Africa expansion. PLoS Genet 1: e82.
62. Ding K, Kullo IJ (2006) Molecular evolution of 5′ flanking regions of 87 candidate genes for atherosclerotic cardiovascular disease. Genet Epidemiol 30: 557-569.
63. Kullo IJ. Ding K (2007) Patterns of population differentiation of candidate genes for cardiovascular disease. BMC genetics 8: 48.
64. Thomas JW, Touchman JW, Blakesley RW, Bouffard GG, Beckstrom-Sternberg SM, et al. (2003) Comparative analyses of multi-species sequences from targeted genomic regions. Nature 424: 788-793.
65. Schaner P, Richards N, Wadhwa A, Aksentijevich I, Kastner D, et al. (2001) Episodic evolution of pyrin in primates: human mutations recapitulate ancestral amino acid states. Nat Genet 27: 318-321.
66. Ng PC, Henikoff S (2003) SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res 31: 3812-3814.
67. Ramensky V, Bork P, Sunyaev S (2002) Human non-synonymous SNPs: server and survey. Nucleic Acids Res 30: 3894-3900.
68. Florea L, Hartzell G, Zhang Z, Rubin GM, Miller W (1998) A computer program for aligning a cDNA sequence with a genomic DNA sequence. Genome Res 8: 967-974.
69. Thompson JD, Higgins DG, Gibson TJ (1994) CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22: 4673-4680.
70. Yang Z, Goldman N, Friday A (1994) Comparison of models for nucleotide substitution used in maximum-likelihood phylogenetic estimation. Mol Biol Evol 11: 316-324.
71. Yang Z, Bielawski JP (2000) Statistical methods for detecting moleculor adaptation. Trends in Ecology and Evolution 15: 496-503.
72. Yang Z (1997) PAML: a program package for phylogenetic analysis by maximum likelihood. Comput Appl Biosci 13: 555-556.
73. Choi SS, Lahn BT (2003) Adaptive evolution of MRG, a neuron-specific gene family implicated in nociception. Genome Res 13: 2252-2259.